Cardiovascular risk reduction
Hypertension is one of the leading risk factors for cardiovascular diseases. The phase IV programme for telmisartan is one of the most extensive ever conducted.
PROTECTION™:
This programme includes nine trials that recruited a total of more than 5,500 patients. It is intended to characterise the clinical therapeutic profile of Pritor/Kinzal.
Weber M. The telmisartan Programme of Research to show Telmisartan End-organ proteCTION (PROTECTION) Programme. J Hypertens 2003;21 (Suppl 6):S37-S46
more
SMOOTH:
This study compares the effects of telmisartan + HCTZ with valsartan + HCTZ in this difficult-to-treat, high-risk population. Telmisartan + HCTZ has proved effective and well tolerated. In comparison with monotherapy, the combination displayed enhanced efficacy and protected against potassium depletion.
McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicentre, randomised, double-blind, placebo-controlled, parallel-group trial. Clin Ther. 2001 Jun;23(6):833-50.
more
page 2 of 3
PROTECTION™:
This programme includes nine trials that recruited a total of more than 5,500 patients. It is intended to characterise the clinical therapeutic profile of Pritor/Kinzal.
Weber M. The telmisartan Programme of Research to show Telmisartan End-organ proteCTION (PROTECTION) Programme. J Hypertens 2003;21 (Suppl 6):S37-S46
more
SMOOTH:
This study compares the effects of telmisartan + HCTZ with valsartan + HCTZ in this difficult-to-treat, high-risk population. Telmisartan + HCTZ has proved effective and well tolerated. In comparison with monotherapy, the combination displayed enhanced efficacy and protected against potassium depletion.
McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicentre, randomised, double-blind, placebo-controlled, parallel-group trial. Clin Ther. 2001 Jun;23(6):833-50.
more
page 2 of 3
